aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more now enrolling a phase  study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced rcc click here for more information latest events th annual bio ceo  investor conference february   latest news aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings june   aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma june   aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target june     aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy management team  aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team about aveo the human response management team board of directors partnerships executive team the aveo oncology management team comprises executives with years of oncology and pharmaceutical industry experience and expertise and a proven track record for success in bringing important new therapies to patients michael p bailey president and ceo michael p bailey serves as president and chief executive officer of aveo and a member of the company’s board of directors bringing more than  years of experience in the pharmaceutical industry to the company he joined aveo in  as the company’s chief commercial officer was named chief business officer in  and assumed his current roles in january  mr bailey joined aveo from synta pharmaceuticals where he served as senior vice president business development and chief commercial officer since  prior to joining synta mr bailey led imclone systems now eli lilly worldwide commercial organization during his nine year tenure at imclone he was responsible for commercial aspects of the planning and launch of erbitux® cetuximab across multiple oncology indications as well as new product planning for the imclone development portfolio which included cyramza® ramucirumab and necitumumab in addition mr bailey was a key member of the strategic leadership committees for imclone and its north american and worldwide partnerships prior to joining imclone mr bailey managed the cardiovascular development portfolio at genentech inc and was a key member of their global commercial partnership teams mr bailey started his career in the pharmaceutical industry as part of smithkline beechams executive marketing development program where he held a variety of commercial roles including sales strategic planning and product management mr bailey received a bs in psychology from st lawrence university and an mba in international marketing from the mendoza college of business at university of notre dame michael n needle md chief medical officer michael n needle md serves as chief medical officer of aveo and brings more than  years of pharmaceutical industry experience in drug development and regulatory affairs this includes central roles in the development of oncology and hematology drugs including erbitux® cetuximab revlimid® lenalidomide and pomalyst® pomolidimide he most recently served as the chief medical officer of array biopharma prior to array dr needle was chief medical officer of the multiple myeloma research foundation and consortium mmrf prior to mmrf he held multiple vice president level positions at celgene in clinical research and development in oncology strategic medical business development and pediatric strategy dr needle also served as the vice president of clinical affairs at imclone systems incorporated dr needle did his fellowship in pediatric hematology  oncology at the childrens hospital medical center and the fred hutchinson cancer research center of the university of washington in seattle and the university of texas md anderson cancer center in houston dr needle has held faculty positions at the university of pennsylvania and columbia university dr needle graduated from binghamton university with a bachelor of arts in physics and received his medical degree from suny downstate medical center in brooklyn new york matthew dallas chief financial officer mr dallas brings to aveo more than  years of financial management experience including  years in the life sciences industry most recently he served as chief financial officer and treasurer of colucid pharmaceuticals a position he held through that biopharmaceutical company’s initial public offering followon offering and subsequent acquisition for approximately  million by eli lilly and company in march  prior to colucid mr dallas served as vice president of finance and treasurer at aveo from  to  a period during which the company was first preparing for the potential launch of tivozanib he previously worked at genzyme corporation nen life sciences and kimberlyclark corporation where he held various positions of increasing responsibility in finance and accounting mr dallas holds a bs in finance from the university of tennessee knoxville emile farhan phd vice president technical operations emile farhan has more than  years of experience in the pharmaceutical industry as the vice president of technical operations he leads all aspects of chemistry manufacturing and control of aveo programs he joined aveo in april  after his tenure at eisai where he served as the head of cmc global operations coordination for the us and europe and as the director of pharmaceutical development at mgi prior to its acquisition by eisai prior to mgi he served as the senior director of product development and manufacturing at mersana therapeutics dr farhan also held several leadership roles at pharmeco from  until its acquisition by johnson matthey in  and at johnson matthey pharma from  to  where he was the senior director of technical operations and scientific affairs dr farhan holds a phd from brandeis university and an ms from the university of massachusetts karuna rubin jd vice president legal affairs and corporate secretary karuna rubin serves as vice president legal affairs and corporate secretary of aveo prior to aveo ms rubin served as an associate at arnold  porter llp and as assistant general counsel at cenveo inc she has extensive experience advising public companies in securities finance mergers and acquisitions and corporate governance ms rubin received her ab in international relations from brown university and her jd from columbia law school   aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy contact us  aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team contact us aveo oncology is very interested in hearing from you please select your area of interest from the form below and you will be contacted shortly aveo oncology one broadway th floor cambridge ma  phone  your name email company address citystatezip country phone areas of interest  product candidates tivozanib ficlatuzumab av monoclonal antibody pipeline human response platform™ other followup  you would like to receive emails on future products and services you have specific questions and would like to be contacted your feedback   aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy our product candidates  aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team our product candidates overview tivozanib ficlatuzumab av av av our product candidates aveo oncology aveo is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need the company is focused on seeking to develop and commercialize its lead candidate tivozanib a potent selective long halflife inhibitor of vascular endothelial growth factor   and  receptors in north america as a treatment for renal cell carcinoma aveo is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of north america and progressing its pipeline of novel therapeutic candidates in cancer cachexia wasting syndrome and pulmonary arterial hypertension pah on june   the committee for medicinal products for human use chmp the scientific committee of the european medicines agency ema recommended fotivda™ tivozanib for approval as a treatment for patients with advanced renal cell carcinoma rcc the chmp’s recommendation is now referred to the european commission ec for a final decision regarding marketing authorization   aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy join our team  aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team join our team we are always looking for enthusiastic and talented individuals who share our passion for science and making an impact on lives of patients and on our community submit your resume here for consideration we welcome your expertise your insight and your enthusiasm to help us develop and commercialize novel drugs that bring new hope to cancer patients aveo oncology is an equal employment opportunity employer that values the strength diversity brings to the workplace   aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy our product candidates  aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team our product candidates overview tivozanib ficlatuzumab av av av our product candidates aveo oncology aveo is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need the company is focused on seeking to develop and commercialize its lead candidate tivozanib a potent selective long halflife inhibitor of vascular endothelial growth factor   and  receptors in north america as a treatment for renal cell carcinoma aveo is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of north america and progressing its pipeline of novel therapeutic candidates in cancer cachexia wasting syndrome and pulmonary arterial hypertension pah on june   the committee for medicinal products for human use chmp the scientific committee of the european medicines agency ema recommended fotivda™ tivozanib for approval as a treatment for patients with advanced renal cell carcinoma rcc the chmp’s recommendation is now referred to the european commission ec for a final decision regarding marketing authorization   aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy aveo pharmaceuticals inc nasdaqaveo aveo pharmaceuticals inc aveo product news news  stocknewscom     follow us stocktwits twitter aveo pharmaceuticals inc aveo product news news aveo – advancing after eusa pharma received a positive opinion from the european medicines agency’s committee for medicinal products for human use recommending marketing authorisation of fotivda tivozanib jun    am  by stocknewscom staff product news key facts surrounding this news item aveo had a powr rating of c neutral coming into today aveo was  above its day moving average coming into today aveo was  below its day moving average coming into today aveo was  above its day moving average coming into today aveo was  above its day moving average coming into today aveo was  above its day moving average coming into today aveo had returned  yeartodate leading up to today’s news versus a  return from the benchmark sp  during the same period more info about aveo pharmaceuticals inc aveo aveo pharmaceuticals inc a biopharmaceutical company develops targeted therapies for patients with cancer and related diseases the company was formerly known as genpath pharmaceuticals inc and changed its name to aveo pharmaceuticals inc in march  aveo pharmaceuticals inc was founded in  and is based in cambridge massachusetts view our full aveo ticker page with ratings news and more aveo at a glance aveo current powr rating™ overall powr rating™ aveo current price   more aveo ratings data and news aveo price reaction the day of this event jun  aveo closing price aveo volume from avgleading up to this eventaveo mo returnafter this eventaveo day returnaveo day returnaveo day return aveo price chart more aveo pharmaceuticals inc aveo news view all eventdate symbol news detail start price end price change powr rating loading please wait view all aveo news page generated in  seconds aveo pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals aveo pharmaceuticals inc  product pipeline review   published may  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample aveo pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘aveo pharmaceuticals inc  product pipeline review  ’ provides an overview of the aveo pharmaceuticals inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by aveo pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of aveo pharmaceuticals inc  the report provides overview of aveo pharmaceuticals inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses aveo pharmaceuticals inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features aveo pharmaceuticals inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate aveo pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for aveo pharmaceuticals inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding aveo pharmaceuticals inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  aveo pharmaceuticals inc snapshot  aveo pharmaceuticals inc overview  key information  key facts  aveo pharmaceuticals inc  research and development overview  key therapeutic areas  aveo pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  pipeline products  outlicensed products  outlicensed productscombination treatment modalities  aveo pharmaceuticals inc  pipeline products glance  aveo pharmaceuticals inc  late stage pipeline products  phase iii productscombination treatment modalities  aveo pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  aveo pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  aveo pharmaceuticals inc  drug profiles  tivozanib hydrochloride  product description  mechanism of action  rd progress  ficlatuzumab  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  gp  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  monoclonal antibody to antagonize fgfr for cancer  product description  mechanism of action  rd progress  monoclonal antibody to antagonize fgfr for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  aveo pharmaceuticals inc  pipeline analysis  aveo pharmaceuticals inc  pipeline products by target  aveo pharmaceuticals inc  pipeline products by route of administration  aveo pharmaceuticals inc  pipeline products by molecule type  aveo pharmaceuticals inc  pipeline products by mechanism of action  aveo pharmaceuticals inc  recent pipeline updates  aveo pharmaceuticals inc  dormant projects  aveo pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  av  tivozanib hydrochloride  aveo pharmaceuticals inc  company statement  aveo pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables aveo pharmaceuticals inc key information  aveo pharmaceuticals inc key facts  aveo pharmaceuticals inc  pipeline by indication   aveo pharmaceuticals inc  pipeline by stage of development   aveo pharmaceuticals inc  monotherapy products in pipeline   aveo pharmaceuticals inc  partnered products in pipeline   aveo pharmaceuticals inc  partnered products combination treatment modalities   aveo pharmaceuticals inc  outlicensed products in pipeline   aveo pharmaceuticals inc  outlicensed products combination treatment modalities   aveo pharmaceuticals inc  phase iii   aveo pharmaceuticals inc  phase ii   aveo pharmaceuticals inc  phase i   aveo pharmaceuticals inc  preclinical   aveo pharmaceuticals inc  discovery   aveo pharmaceuticals inc  pipeline by target   aveo pharmaceuticals inc  pipeline by route of administration   aveo pharmaceuticals inc  pipeline by molecule type   aveo pharmaceuticals inc  pipeline products by mechanism of action   aveo pharmaceuticals inc  recent pipeline updates   aveo pharmaceuticals inc  dormant developmental projects  aveo pharmaceuticals inc  discontinued pipeline products   aveo pharmaceuticals inc subsidiaries  list of figures aveo pharmaceuticals inc  pipeline by top  indication   aveo pharmaceuticals inc  pipeline by stage of development   aveo pharmaceuticals inc  monotherapy products in pipeline   aveo pharmaceuticals inc  partnered products in pipeline   aveo pharmaceuticals inc  pipeline by top  target   aveo pharmaceuticals inc  pipeline by route of administration   aveo pharmaceuticals inc  pipeline by molecule type   aveo pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global and china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enh read more united states laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the united states laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhanc read more europe laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the europe laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more china laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the china laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the u read more global laboratory ventilators market professional survey report forecast  mar  sp consulting  pages    code  mrs   this report studies laboratory ventilators in global market especially in north america china europe southeast asia japan and india with production revenue consumption import and export in these regions from  to  and forecast to  this report focuses on top manufacturers in global market with production price revenue and market share for each manufacturer covering harvard apparatus parr instrument harvard bioscience columbus instruments company  company   b read more global laboratory ventilators sales market report forecast  mar  sp consulting  pages    code  mrs   the report offers a comprehensive evaluation of the market it does so via indepth insights understanding market evolution by tracking historical developments and analyzing the present scenario and future projections based on optimistic and likely scenarios each research report serves as a repository of analysis and information for every facet of the market including but not limited to regional markets technology developments types applications and the competitive landscape the read more global laboratory ventilators market research report forecast  mar  sp consulting  pages    code  mrs   the global laboratory ventilators market research report forecast  is a valuable source of insightful data for business strategists it provides the laboratory ventilators industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this laboratory ventilators market study provides comprehensive data which enhances the read more global and china medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the global and china medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive da read more united states medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the united states medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data read more europe medical bone densitometers market research report forecast  mar  sp consulting  pages    code  mrs   the europe medical bone densitometers market research report forecast  is a valuable source of insightful data for business strategists it provides the medical bone densitometers industry overview with growth analysis and historical  futuristic cost revenue demand and supply data as applicable the research analysts provide an elaborate description of the value chain and its distributor analysis this medical bone densitometers market study provides comprehensive data which e read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports aveo pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports aveo pharmaceuticals inc  product pipeline review   aveo pharmaceuticals inc  product pipeline review   wgr  may  global  pages global markets direct description table of content sample report enquiry before buy related reports aveo pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘aveo pharmaceuticals inc  product pipeline review  ’ provides an overview of the aveo pharmaceuticals inc’s pharmaceutical research and development focus the report provides comprehensive information on the therapeutics under development by aveo pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basis the report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage note certain sections in the report may be removed or altered based on the availability and relevance of data scope  the report provides a snapshot of the pipeline therapeutic landscape of aveo pharmaceuticals inc  the report provides overview of aveo pharmaceuticals inc including its business description key facts and locations and subsidiaries  the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities  the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages  the report assesses aveo pharmaceuticals inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type  the report features aveo pharmaceuticals inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projects reasons to buy  evaluate aveo pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  gain strategically significant competitor information analysis and insights to formulate effective rd strategies  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  identify and understand important and diverse types of therapeutics under development for aveo pharmaceuticals inc  identify potential new clients or partners in the target demographic  plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics  devise corrective measures for pipeline projects by understanding aveo pharmaceuticals inc’s pipeline depth and focus of pipeline therapeutics  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contents table of contents  list of tables  list of figures  aveo pharmaceuticals inc snapshot  aveo pharmaceuticals inc overview  key information  key facts  aveo pharmaceuticals inc  research and development overview  key therapeutic areas  aveo pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  pipeline products  outlicensed products  outlicensed productscombination treatment modalities  aveo pharmaceuticals inc  pipeline products glance  aveo pharmaceuticals inc  late stage pipeline products  phase iii productscombination treatment modalities  aveo pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  aveo pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  discovery productscombination treatment modalities  aveo pharmaceuticals inc  drug profiles  tivozanib hydrochloride  product description  mechanism of action  rd progress  ficlatuzumab  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  gp  product description  mechanism of action  rd progress  av  product description  mechanism of action  rd progress  monoclonal antibody to antagonize fgfr for cancer  product description  mechanism of action  rd progress  monoclonal antibody to antagonize fgfr for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  monoclonal antibody to target notch for cancer  product description  mechanism of action  rd progress  aveo pharmaceuticals inc  pipeline analysis  aveo pharmaceuticals inc  pipeline products by target  aveo pharmaceuticals inc  pipeline products by route of administration  aveo pharmaceuticals inc  pipeline products by molecule type  aveo pharmaceuticals inc  pipeline products by mechanism of action  aveo pharmaceuticals inc  recent pipeline updates  aveo pharmaceuticals inc  dormant projects  aveo pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  av  tivozanib hydrochloride  aveo pharmaceuticals inc  company statement  aveo pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables aveo pharmaceuticals inc key information  aveo pharmaceuticals inc key facts  aveo pharmaceuticals inc  pipeline by indication   aveo pharmaceuticals inc  pipeline by stage of development   aveo pharmaceuticals inc  monotherapy products in pipeline   aveo pharmaceuticals inc  partnered products in pipeline   aveo pharmaceuticals inc  partnered products combination treatment modalities   aveo pharmaceuticals inc  outlicensed products in pipeline   aveo pharmaceuticals inc  outlicensed products combination treatment modalities   aveo pharmaceuticals inc  phase iii   aveo pharmaceuticals inc  phase ii   aveo pharmaceuticals inc  phase i   aveo pharmaceuticals inc  preclinical   aveo pharmaceuticals inc  discovery   aveo pharmaceuticals inc  pipeline by target   aveo pharmaceuticals inc  pipeline by route of administration   aveo pharmaceuticals inc  pipeline by molecule type   aveo pharmaceuticals inc  pipeline products by mechanism of action   aveo pharmaceuticals inc  recent pipeline updates   aveo pharmaceuticals inc  dormant developmental projects  aveo pharmaceuticals inc  discontinued pipeline products   aveo pharmaceuticals inc subsidiaries  list of figures aveo pharmaceuticals inc  pipeline by top  indication   aveo pharmaceuticals inc  pipeline by stage of development   aveo pharmaceuticals inc  monotherapy products in pipeline   aveo pharmaceuticals inc  partnered products in pipeline   aveo pharmaceuticals inc  pipeline by top  target   aveo pharmaceuticals inc  pipeline by route of administration   aveo pharmaceuticals inc  pipeline by molecule type   aveo pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send aveo stock price  aveo pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers amd  xrx  wynn  cfg  has  swk  itw  mat  latest newsall times eastern a goldman sachs stock drops  after analyst downgrade a goldman sachs stock price target cut to  from  at ubs a goldman sachs downgraded to neutral from buy at ubs a updated exxon earnings will stock trade higher on expected secondquarter beat a updated chipotle earnings media coverage of the latest illness scare will put earnings targets at risk a updated alphabet earnings a  billion hit for google potential youtube results for investors a updated why some older investors might invest in a longterm time horizon a updated a yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ a updated good news if you love coffee a updated the states where people spend the most on lotto tickets to be replaced home investing quotes stocks united states aveo overview compare quotes stock screener earnings calendar sectors nasdaq aveo us nasdaq join td ameritrade find a broker aveo pharmaceuticals inc watchlist createaveoalert open last updated jul    am edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones aveo pharma surges  on recommendation for european approval of its cancer drug aveo pharmaceuticals inc shares surged as much as  in extremely heavy morning trade friday after the companys cancer drug was recommended for approval in europe the decision was made by a scientific committee of the european medicines agency and will be considered by the european commission with a decision expected in about  days the company said the drug tivozanib is being licensed in europe by eusa pharma inc tivozanib is intended for advanced renal cell carcinoma which is the most common type of kidney cancer and is expected to be one of the fastest growing cancers in the next decade aveo failed to receive food and drug administration approval for tivozanib back in  the company has an ongoing phase  trial in thirdline renal cell carcinoma which is expected to read out in the first quarter of  european approval of tivozanib would add significant resources to our balance sheet as we work toward the anticipated readout aveo chief executive michael bailey said including a  million research and development reimbursement payment and up to  million in additional milestone payments from eusa pharma aveo shares have surged  over the last three months to  per share compared with a  rise in the sp   jun   at  am et by emma court aveo pharma surges  on recommendation for european approval of its cancer drug aveo pharma surges  on recommendation for european approval of its cancer drug jun   at  am et by emma court aveo pharmaceuticals started at outperform with  stock price target at fbr  co mar   at  am et by tomi kilgore bed bath  beyond shares sink as sales miss consensus jan   at  pm et by wallace witkowski aveo loss widens on revenue drop shares down apr   at  am et updates advisories and surprises aug   at  pm et by marketwatch thursday’s biggest gaining and declining stocks aug   at  pm et by marketwatch aveo sinks  after fda update earnings aug   at  am et by val brickates kennedy aveo dives  on fda update aug   at  am et by val brickates kennedy dividends dont lie jan   at  am et by mick weinstein aveo cancer treatment meets goal but shares drop jan   at  pm et aveo reports progress with cancerdrug candidate jan   at  am et updates advisories and surprises jul   at  pm et by marketwatch aveo climbs on earnings outlook jul   at  pm et by val brickates kennedy wednesday’s biggest gaining and declining stocks jun   at  pm et by kate gibson regeneron energizes biotech stocks jun   at  pm et by val brickates kennedy aveo shares tumble  on stock offer pricing jun   at  am et by val brickates kennedy inspire aveo take lead in drugstocks trading feb   at  pm et by val brickates kennedy aveo shares jump on astellas pact feb   at  am et by val brickates kennedy stocks to watch bank of america finish line ak steel sonic among the companies with shares expected to trade actively in friday’s session are bank of america corp finish line inc ak steel holding corp sonic corp and aveo pharmaceuticals inc jun   at  am et on the wall street journal stocks to watch twitter fedex pfizer jun   at  am et on the wall street journal aveo shares jump after company regains rights to antibody mar   at  pm et on the wall street journal cfo moves immunogen kmg chemicals dec   at  pm et on the wall street journal cfo moves aveo pharmaceuticals hillrom covanta dec   at  pm et on the wall street journal stocks to watch mcdonalds apricus dynavax jun   at  am et on the wall street journal stocks to watch ambarella mattress firm unitedhealth jun   at  am et on the wall street journal stocks to watch abercrombie infloblox pandora may   at  am et on the wall street journal stocks to watch citigroup herbalife cbs jan   at  am et on the wall street journal quantum aveo pharmaceuticals biggest price decliners qtm aveo jan   at  pm et on the wall street journal stocks to watch mgic molycorp and more jan   at  am et on the wall street journal venture capitalists enjoying more deals ipos may   at  pm et on the wall street journal crude carriers aveo ipos fall mar   at  am et on the wall street journal sensata rises on stock debut mar   at  am et on the wall street journal recent news other news press releases heres why aveo oncology rose as much as  today jul   at  pm et on motley fool heres why aveo oncology fell as much as  today jul   at  pm et on motley fool company news for july   companies in the news are brkaspaaveoabcounh jul   at  am et on zackscom aveo set to continue up move on looming eu approval of tivozanib for kidney cancer shares ahead  premarket aveo set to continue up move on looming eu approval of tivozanib for kidney cancer shares ahead  premarket jul   at  am et on seeking alpha aveo pharmaceuticals aveo worth a look stock up  aveo pharmaceuticals inc aveo shares rose around  in the last trading session jul   at  am et on zackscom why aveo pharmaceuticals inc aveo stock is soaring today why aveo pharmaceuticals inc aveo stock is soaring today jul   at  pm et on investorplacecom biotech forum daily digest  biotech fritters away some gains  fda calendar events in july biotech forum daily digest  biotech fritters away some gains  fda calendar events in july jul   at  am et on seeking alpha biotech stock roundup eu nod for regeneron ra drug portola soars on fda nod key highlights in the biotech sector include fda approval for portolas ptla anticoagulant and eu approval for regenerons rheumatoid arthritis ra drug jun   at  am et on zackscom heres why aveo oncology rose as much as  today jun   at  pm et on motley fool aveo comeback highlights a transatlantic split aveo comeback highlights a transatlantic split jun   at  am et on seeking alpha  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha aveos kidney cancer candidate gets chmp recommendation aveo pharmaceuticals inc aveo announced on friday that the committee for medicinal products for human use chmp has recommended the approval of its lead candidate fotivda tivozanib for the treatment of advanced renal cell carcinoma rcc jun   at  am et on zackscom aveo pharmaceuticals inc aveo raises funds to support clinical development program shares fall aveo pharmaceuticals inc nasdaqaveo stock tumbled nearly  in early trading tuesday after the drug  jun   at  am et on smarteranalyst biotech forum daily digest  biotech soars spotlight on novacure biotech forum daily digest  biotech soars spotlight on novacure jun   at  pm et on seeking alpha european ad com backs aveos tivozanib for kidney cancer shares up  premarket european ad com backs aveos tivozanib for kidney cancer shares up  premarket jun   at  am et on seeking alpha a glimpse into two rising biotechs aveo pharmaceuticals inc aveo idera pharmaceuticals inc idra aveo pharmaceuticals shares skyrocket on positive chmp opinion its a very rewarding trading day for investors in  jun   at  am et on smarteranalyst aveo reaches enrollment target in pivotal tivozanib study aveo pharmaceuticals inc aveo announced that the phase iii study tivo evaluating tivozanib in patients with refractory advanced renal cell carcinoma rcc has reached its enrollment target jun   at  am et on zackscom  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha why is aveo pharmaceuticals aveo up  since the last earnings report aveo pharmaceuticals aveo reported earnings  days ago whats next for the stock we take a look at earnings estimates for some clues jun   at  am et on zackscom  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  pm et on seeking alpha stock performance review on biotech industry  athersys aveo pharma heat biologics and ignyta stock performance review on biotech industry  athersys aveo pharma heat biologics and ignyta jul   at  am et on pr newswire  prf asset acquisitions accelerate in healthcare sector boosting potential revenue growth asset acquisitions accelerate in healthcare sector boosting potential revenue growth jul   at  am et on pr newswire  prf todays research reports on stocks to watch aveo pharmaceuticals and clean diesel technologies todays research reports on stocks to watch aveo pharmaceuticals and clean diesel technologies jul   at  am et on accesswire aveo pharmaceuticals regulatory decision from european commission expected soon aveo pharmaceuticals regulatory decision from european commission expected soon jul   at  am et on accesswire todays research reports on trending tickers aveo pharmaceuticals and cara therapeutics todays research reports on trending tickers aveo pharmaceuticals and cara therapeutics jun   at  am et on accesswire aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings jun   at  am et on businesswire  bzx biotech stocks showing signs of resurgence biotech stocks showing signs of resurgence jun   at  am et on pr newswire  prf todays research reports on stocks to watch portola and aveo todays research reports on stocks to watch portola and aveo jun   at  am et on accesswire aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma jun   at  am et on businesswire  bzx aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target jun   at  am et on businesswire  bzx aveo oncology announces phase  tinivo trial of tivozanib and opdivo® nivolumab in rcc advances to phase  aveo oncology announces phase  tinivo trial of tivozanib and opdivo® nivolumab in rcc advances to phase  jun   at  am et on businesswire  bzx aveo oncology and biodesix announce results from two investigatorsponsored phase  studies of hgf targeted antibody ficlatuzumab at the  asco annual meeting aveo oncology and biodesix announce results from two investigatorsponsored phase  studies of hgf targeted antibody ficlatuzumab at the  asco annual meeting jun   at  pm et on businesswire  bzx aveo oncology announces completion of a chmp oral explanation for tivozanib as a treatment of firstline renal cell carcinoma aveo oncology announces completion of a chmp oral explanation for tivozanib as a treatment of firstline renal cell carcinoma may   at  am et on businesswire  bzx research reports initiation on biotech stocks  agenus athersys actinium pharma and aveo pharma research reports initiation on biotech stocks  agenus athersys actinium pharma and aveo pharma may   at  am et on pr newswire  prf aveo announces appointment of matthew dallas as chief financial officer aveo announces appointment of matthew dallas as chief financial officer may   at  am et on businesswire  bzx aveo issues statement regarding the passing of lead director henri a termeer aveo issues statement regarding the passing of lead director henri a termeer may   at  am et on businesswire  bzx aveo oncology announces receipt of uspto notice of allowance related to av aveo oncology announces receipt of uspto notice of allowance related to av may   at  am et on businesswire  bzx todays research reports on biotech stocks to watch aveo pharmaceuticals and pharmathene todays research reports on biotech stocks to watch aveo pharmaceuticals and pharmathene may   at  am et on accesswire aveo reports first quarter  financial results and provides business update aveo reports first quarter  financial results and provides business update may   at  am et on businesswire  bzx aveo announces presentations at the  asco annual meeting apr   at  am et on businesswire  bzx aveo pharmaceuticals inc aveo pharmaceuticals inc operates as a biopharmaceutical company which engages in the advancement of therapeutics for oncology and other areas of unmet medical need its products include tivozanib ficlatuzmab av av and av it focuses on the development of its lead candidate tivozanib in north america as a treatment for renal cell carcinoma and other cancers the company was founded by ronald a depinho lynda chin and kenneth e weg on october   and is headquartered in cambridge ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings rbc capital upgrades aveo pharmaceuticals to sector perform mar   at  am et on benzingacom benzingas top upgrades mar   at  am et on benzingacom update rbc capital markets upgrades aveo pharmaceuticals on progress in multiple areas mar   at  am et on benzingacom competitors name chg  market cap amgen inc  b arqule inc  m regeneron pharmaceuticals inc  b biogen inc  b bristolmyers squibb co  b competitor data provided by partner content trending tickers powered by bzun  momo  gnca  hal  cmg  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience stocks index  markets index bulletin investor alert london markets close in currencies futures metals stocks stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agoldman sachs stock drops  after analyst downgrade agoldman sachs stock price target cut to  from  at ubs agoldman sachs downgraded to neutral from buy at ubs aexxon earnings will stock trade higher on expected secondquarter beat achipotle earnings media coverage of the latest illness scare will put earnings targets at risk aalphabet earnings a  billion hit for google potential youtube results for investors awhy some older investors might invest in a longterm time horizon aa yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ agood news if you love coffee athe states where people spend the most on lotto tickets a‘game of thrones’ this computer model predicts who will be killed off — or survive ateaching people how to invest is one of the best marketing moves an adviser can make adollar edges higher ahead of fed meeting but remains lower for july awhy ‘game of thrones’ characters are smart to prefer status over money anolan’s cinematic vision in ‘dunkirk’ is hollywood’s best defense against netflix aus stocks under pressure as earnings roll in aexistinghome sales fall in june as prices soar to fresh record aimax shares are up more than  awho president trump can pardon and who he can’t aus dollar slightly extends gains after housing data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stocks index  markets index bulletin investor alert london markets close in currencies futures metals stocks stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies browse stocks stocks az abcdefghijklmnopqrstuvwxyzother browse by location argentina australia austria bahamas bahrain belgium bermuda botswana brazil british virgin islands canada cayman islands chile china colombia curacao cyprus czech republic denmark egypt estonia finland france germany gibraltar greece hong kong hungary iceland india indonesia ireland isle of man israel italy japan jordan kazakhstan kuwait latvia lebanon liechtenstein lithuania luxembourg malaysia malta mauritius mexico monaco money rates morocco namibia netherlands new zealand norway oman pakistan panama peru philippines poland portugal qatar romania russia saudi arabia singapore slovakia slovenia south africa south korea spain sri lanka sweden switzerland taiwan thailand tunisia turkey ukraine united arab emirates united states venezuela western samoa log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agoldman sachs stock drops  after analyst downgrade agoldman sachs stock price target cut to  from  at ubs agoldman sachs downgraded to neutral from buy at ubs aexxon earnings will stock trade higher on expected secondquarter beat achipotle earnings media coverage of the latest illness scare will put earnings targets at risk aalphabet earnings a  billion hit for google potential youtube results for investors awhy some older investors might invest in a longterm time horizon aa yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ agood news if you love coffee athe states where people spend the most on lotto tickets a‘game of thrones’ this computer model predicts who will be killed off — or survive ateaching people how to invest is one of the best marketing moves an adviser can make adollar edges higher ahead of fed meeting but remains lower for july awhy ‘game of thrones’ characters are smart to prefer status over money anolan’s cinematic vision in ‘dunkirk’ is hollywood’s best defense against netflix aus stocks under pressure as earnings roll in aexistinghome sales fall in june as prices soar to fresh record aimax shares are up more than  awho president trump can pardon and who he can’t aus dollar slightly extends gains after housing data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  stockscountryunited states index  markets index bulletin investor alert london markets close in currencies futures metals stocks stocks rates funds bonds benchmarks real estate investment trusts futures american depository receipt stocks exchange traded notes warrants indexes exchange traded funds currencies crypto currencies location united states name exchange sector  communique laboratory inc ocqlf ootc software  property insurance holdings inc pih xnas nonlife insurance flowerscom inc cl a flws xnas specialty retail pm industries inc opmz ootc food products st capital bank ca fisb ootc banking st constitution bancorp fccy xnas banking st nrg corp fnrc ootc oil extraction st source corp srce xnas banking  motors inc etfm ootc automobiles st century fox inc cl a foxa xnas broadcasting st century fox inc cl b fox xnas broadcasting vianet group inc adr vnet xnas internetonline nd century group inc xxii xase biotechnology  kid doc inc tvmd ootc healthcare provision u inc twou xnas software xleveraged long etracs linked to wells fargo business development co index  bdcl arcx major international banks xleveraged long etracs wells fargo business development lbdc arcx major international banks d eye solutions inc tdey ootc motion picturesound recording d pioneer systems inc dpsm ootc software d systems corp ddd xnys computersconsumer electronics dicon corp tdcp ootc software dshoppingcom thds ootc mixed retailing dx industries inc dddx ootc computersconsumer electronics i group plc adr tgopy ootc finance companies m co mmm xnys diversified holding companies pea international inc tpnl xotc accounting power energy group inc pspw ootc renewable energy generation tl technologies corp ttmzf ootc advertisingmarketingpublic relations  property management inc ftpm ootc real estate agentsbrokers cable tv international inc catv ootc diversified business services licensing corp fourq ootc diversified business services com ltd adr wbai xnys gambling industries job inc adr jobs xnas employmenttraining services com inc adr wuba xnys consumer services barz international inc barz ootc networking n plus inc fplsf ootc commodity chemicals d global technologies inc sixd ootc computer services  renewable energy corp rnwr ootc multiutilities  energy ltd adr tngry ootc oil extraction  holdings plc eihdf ootc gambling industries point energy partners lp cafd xnas renewable energy generation x inc eght xnas wired telecommunications services a clean slate inc drwn ootc diversified business services aw revenue royalties income fund awrrf ootc restaurants a h belo corp series a ahc xnys publishing a schulman inc shlm xnas commodity chemicals a schulman inc  pfd slmnp ootc commodity chemicals ad makepeace co make ootc farming am castle  co cas xnys wholesalers ao smith corp aos xnys building materialsproducts ap moellermaersk as adr amkby ootc water transportshipping ap moellermaersk as series a amkaf ootc water transportshipping ap moellermaersk as series b amkbf ootc water transportshipping as roma spa asraf ootc recreational services a group inc awon ootc tobacco a networks inc aten xnys computer services a milk co ltd acopf ootc biotechnology aac holdings inc aac xnys healthcare provision aac technologies holdings inc aacaf ootc industrial electronics aac technologies holdings inc adr aacay ootc industrial electronics aaon inc aaon xnas building materialsproducts aap inc aapj ootc food products aar corp air xnys aerospace productsparts aarons inc aan xnys consumer services ab science sa abscf ootc pharmaceuticals ab svensk exportkredit elements linked to mlcx biofuels index total return fue arcx finance companies ab svensk exportkredit elements linked to mlcx grain index total return gru arcx finance companies abt financial corp abto ootc banking abacus mining  exploration corp abcff ootc general mining abakan inc abki ootc industrial products abattis bioceuticals corp attbf ootc biotechnology abaxis inc abax xnas medical equipmentsupplies abb ltd ablzf ootc industrial machinery abb ltd adr abb xnys industrial machinery abbott laboratories abt xnys pharmaceuticals abbvie inc abbv xnys biotechnology abby inc abby ootc oil extraction abcam plc abczf ootc biotechnology abcam plc adr abczy ootc biotechnology abco energy inc abce ootc industrial machinery abcourt mines inc abmbf ootc general mining aben resources ltd abnaf ootc general mining abengoa sa b agoaf ootc construction abeona therapeutics inc abeo xnas biotechnology abeona therapeutics inc wt abeow xnas abercrombie  fitch co anf xnys clothing retail aberdeen asiapacific income fund inc fax xase closedend funds aberdeen asiapacific income investment co ltd abakf ootc closedend funds aberdeen asset management plc abdnf ootc investment advisors aberdeen asset management plc adr abdny ootc investment advisors aberdeen australia equity fund inc iaf xase closedend funds aberdeen chile fund inc ch xase closedend funds aberdeen emerging markets smaller company opportunities fund inc abe xase closedend funds aberdeen global income fund inc fco xase closedend funds aberdeen greater china fund inc gch xnys closedend funds aberdeen indonesia fund inc if xase closedend funds aberdeen international inc aabvf ootc general mining aberdeen israel fund inc isl xase closedend funds aberdeen japan equity fund inc jeq xnys closedend funds aberdeen latin america equity fund inc laq xase closedend funds aberdeen singapore fund inc sgf xnys closedend funds abertis infraestructuras sa adr abrty ootc transportation services ability inc abil xnas precision products ability inc wt abiwf ootc abiomed inc abmd xnas medical equipmentsupplies abitibi royalties inc atbyf ootc general mining able energy inc able ootc gas utilities ablynx nv ablyf ootc biotechnology abm industries inc abm xnys diversified business services abraxas petroleum corp axas xnas oil extraction absecon bancorp ascn ootc banking absolute health  fitness inc ahfi ootc recreational services absolute software corp alswf ootc software abt holdings inc abot ootc precious metals abtech holdings inc abhd ootc industrial machinery abv consulting inc abvn ootc advertisingmarketingpublic relations ac immune sa aciu xnas biotechnology acacia communications inc acia xnas networking acacia diversified holdings inc acca ootc specialty retail acacia mining plc abglf ootc gold acacia research corp  acacia technologies actg xnas diversified business services acadia healthcare co inc achc xnas healthcare provision acadia pharmaceuticals inc acad xnas biotechnology acadia realty trust akr xnys acadian timber corp acazf ootc forestry  wood products acasti pharma inc acst xnas pharmaceuticals accelera innovations inc acnv ootc healthcare provision accelerate diagnostics inc axdx xnas biotechnology accelerize inc aclz xotc life insurance acceleron pharma inc xlrn xnas biotechnology accenture plc cl a acn xnys diversified business services access national corp ancx xnas banking access power inc accr ootc wired telecommunications services access worldwide communications inc awwc ootc advertisingmarketingpublic relations acciona sa acxif ootc construction acco brands corp acco xnys nondurable household products accor sa acrff ootc hotels accor sa adr accyy ootc hotels accordia golf co ltd acgff ootc recreational services accredited mortgage loan reit trust  perp cum pfd series a ahhap ootc mortgages accretive health inc achi ootc healthcare provision accuray inc aray xnas medical equipmentsupplies accuride corp acw xnys auto  commercial vehicle parts acelrx pharmaceuticals inc acrx xnas pharmaceuticals acer inc gdr reg s aceyy ootc computersconsumer electronics acerus pharmaceuticals corp trlpf ootc biotechnology aceto corp acet xnas specialty chemicals achaogen inc akao xnas biotechnology achillion pharmaceuticals inc achn xnas biotechnology aci worldwide inc aciw xnas software «» log in  am edt july   marketstatecountryus new york open marketstatecountryuk london open marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest agoldman sachs stock drops  after analyst downgrade agoldman sachs stock price target cut to  from  at ubs agoldman sachs downgraded to neutral from buy at ubs aexxon earnings will stock trade higher on expected secondquarter beat achipotle earnings media coverage of the latest illness scare will put earnings targets at risk aalphabet earnings a  billion hit for google potential youtube results for investors awhy some older investors might invest in a longterm time horizon aa yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ agood news if you love coffee athe states where people spend the most on lotto tickets a‘game of thrones’ this computer model predicts who will be killed off — or survive ateaching people how to invest is one of the best marketing moves an adviser can make adollar edges higher ahead of fed meeting but remains lower for july awhy ‘game of thrones’ characters are smart to prefer status over money anolan’s cinematic vision in ‘dunkirk’ is hollywood’s best defense against netflix aus stocks under pressure as earnings roll in aexistinghome sales fall in june as prices soar to fresh record aimax shares are up more than  awho president trump can pardon and who he can’t aus dollar slightly extends gains after housing data loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  aveo stock price  aveo pharmaceuticals inc stock quote us nasdaq  marketwatch sections watchlist signup • login search bulletin us europe asia fx rates futures range d d m m m y y dow    sp     nasdaq    globaldow    gold    oil    sp  movers amd  xrx  wynn  cfg  has  swk  itw  mat  latest newsall times eastern a goldman sachs stock drops  after analyst downgrade a goldman sachs stock price target cut to  from  at ubs a goldman sachs downgraded to neutral from buy at ubs a updated exxon earnings will stock trade higher on expected secondquarter beat a updated chipotle earnings media coverage of the latest illness scare will put earnings targets at risk a updated alphabet earnings a  billion hit for google potential youtube results for investors a updated why some older investors might invest in a longterm time horizon a updated a yearold ‘dunkirk’ survivor laments current state of the world ‘it never ends’ a updated good news if you love coffee a updated the states where people spend the most on lotto tickets to be replaced home investing quotes stocks united states aveo overview compare quotes stock screener earnings calendar sectors nasdaq aveo us nasdaq join td ameritrade find a broker aveo pharmaceuticals inc watchlist createaveoalert open last updated jul    am edt real time quote     previous close  advanced charting d d m m m ytd y y all   vol advanced charting  vs avg volume k  day avg  m open  last   day lowhigh  day range   week lowhigh  your watchlist customize marketwatch have watchlists log in to see them here or sign up to get started create account … or log in symbol last chg chg  no items in watchlist there are currently no items in this watchlist add ticker to watchlist go to your watchlist no saved watchlists create a list of the investments you want to track create watchlist …or try this starter list uh oh something went wrong while loading watchlist go to watchlist recently viewed tickers no recent tickers visit a quote page and your recently viewed tickers will be displayed here search tickers overview profile news charts financials historical quotes analyst estimates options sec filings insiders key data open  day range     week range    market cap m shares outstanding m public float m beta  rev per employee k pe ratio na eps  yield na dividend na exdividend date na short interest m   of float shorted  average volume m performance  day   month   month  ytd   year  recent news marketwatch other dow jones aveo pharma surges  on recommendation for european approval of its cancer drug aveo pharmaceuticals inc shares surged as much as  in extremely heavy morning trade friday after the companys cancer drug was recommended for approval in europe the decision was made by a scientific committee of the european medicines agency and will be considered by the european commission with a decision expected in about  days the company said the drug tivozanib is being licensed in europe by eusa pharma inc tivozanib is intended for advanced renal cell carcinoma which is the most common type of kidney cancer and is expected to be one of the fastest growing cancers in the next decade aveo failed to receive food and drug administration approval for tivozanib back in  the company has an ongoing phase  trial in thirdline renal cell carcinoma which is expected to read out in the first quarter of  european approval of tivozanib would add significant resources to our balance sheet as we work toward the anticipated readout aveo chief executive michael bailey said including a  million research and development reimbursement payment and up to  million in additional milestone payments from eusa pharma aveo shares have surged  over the last three months to  per share compared with a  rise in the sp   jun   at  am et by emma court aveo pharma surges  on recommendation for european approval of its cancer drug aveo pharma surges  on recommendation for european approval of its cancer drug jun   at  am et by emma court aveo pharmaceuticals started at outperform with  stock price target at fbr  co mar   at  am et by tomi kilgore bed bath  beyond shares sink as sales miss consensus jan   at  pm et by wallace witkowski aveo loss widens on revenue drop shares down apr   at  am et updates advisories and surprises aug   at  pm et by marketwatch thursday’s biggest gaining and declining stocks aug   at  pm et by marketwatch aveo sinks  after fda update earnings aug   at  am et by val brickates kennedy aveo dives  on fda update aug   at  am et by val brickates kennedy dividends dont lie jan   at  am et by mick weinstein aveo cancer treatment meets goal but shares drop jan   at  pm et aveo reports progress with cancerdrug candidate jan   at  am et updates advisories and surprises jul   at  pm et by marketwatch aveo climbs on earnings outlook jul   at  pm et by val brickates kennedy wednesday’s biggest gaining and declining stocks jun   at  pm et by kate gibson regeneron energizes biotech stocks jun   at  pm et by val brickates kennedy aveo shares tumble  on stock offer pricing jun   at  am et by val brickates kennedy inspire aveo take lead in drugstocks trading feb   at  pm et by val brickates kennedy aveo shares jump on astellas pact feb   at  am et by val brickates kennedy stocks to watch bank of america finish line ak steel sonic among the companies with shares expected to trade actively in friday’s session are bank of america corp finish line inc ak steel holding corp sonic corp and aveo pharmaceuticals inc jun   at  am et on the wall street journal stocks to watch twitter fedex pfizer jun   at  am et on the wall street journal aveo shares jump after company regains rights to antibody mar   at  pm et on the wall street journal cfo moves immunogen kmg chemicals dec   at  pm et on the wall street journal cfo moves aveo pharmaceuticals hillrom covanta dec   at  pm et on the wall street journal stocks to watch mcdonalds apricus dynavax jun   at  am et on the wall street journal stocks to watch ambarella mattress firm unitedhealth jun   at  am et on the wall street journal stocks to watch abercrombie infloblox pandora may   at  am et on the wall street journal stocks to watch citigroup herbalife cbs jan   at  am et on the wall street journal quantum aveo pharmaceuticals biggest price decliners qtm aveo jan   at  pm et on the wall street journal stocks to watch mgic molycorp and more jan   at  am et on the wall street journal venture capitalists enjoying more deals ipos may   at  pm et on the wall street journal crude carriers aveo ipos fall mar   at  am et on the wall street journal sensata rises on stock debut mar   at  am et on the wall street journal recent news other news press releases heres why aveo oncology rose as much as  today jul   at  pm et on motley fool heres why aveo oncology fell as much as  today jul   at  pm et on motley fool company news for july   companies in the news are brkaspaaveoabcounh jul   at  am et on zackscom aveo set to continue up move on looming eu approval of tivozanib for kidney cancer shares ahead  premarket aveo set to continue up move on looming eu approval of tivozanib for kidney cancer shares ahead  premarket jul   at  am et on seeking alpha aveo pharmaceuticals aveo worth a look stock up  aveo pharmaceuticals inc aveo shares rose around  in the last trading session jul   at  am et on zackscom why aveo pharmaceuticals inc aveo stock is soaring today why aveo pharmaceuticals inc aveo stock is soaring today jul   at  pm et on investorplacecom biotech forum daily digest  biotech fritters away some gains  fda calendar events in july biotech forum daily digest  biotech fritters away some gains  fda calendar events in july jul   at  am et on seeking alpha biotech stock roundup eu nod for regeneron ra drug portola soars on fda nod key highlights in the biotech sector include fda approval for portolas ptla anticoagulant and eu approval for regenerons rheumatoid arthritis ra drug jun   at  am et on zackscom heres why aveo oncology rose as much as  today jun   at  pm et on motley fool aveo comeback highlights a transatlantic split aveo comeback highlights a transatlantic split jun   at  am et on seeking alpha  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha aveos kidney cancer candidate gets chmp recommendation aveo pharmaceuticals inc aveo announced on friday that the committee for medicinal products for human use chmp has recommended the approval of its lead candidate fotivda tivozanib for the treatment of advanced renal cell carcinoma rcc jun   at  am et on zackscom aveo pharmaceuticals inc aveo raises funds to support clinical development program shares fall aveo pharmaceuticals inc nasdaqaveo stock tumbled nearly  in early trading tuesday after the drug  jun   at  am et on smarteranalyst biotech forum daily digest  biotech soars spotlight on novacure biotech forum daily digest  biotech soars spotlight on novacure jun   at  pm et on seeking alpha european ad com backs aveos tivozanib for kidney cancer shares up  premarket european ad com backs aveos tivozanib for kidney cancer shares up  premarket jun   at  am et on seeking alpha a glimpse into two rising biotechs aveo pharmaceuticals inc aveo idera pharmaceuticals inc idra aveo pharmaceuticals shares skyrocket on positive chmp opinion its a very rewarding trading day for investors in  jun   at  am et on smarteranalyst aveo reaches enrollment target in pivotal tivozanib study aveo pharmaceuticals inc aveo announced that the phase iii study tivo evaluating tivozanib in patients with refractory advanced renal cell carcinoma rcc has reached its enrollment target jun   at  am et on zackscom  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  am et on seeking alpha why is aveo pharmaceuticals aveo up  since the last earnings report aveo pharmaceuticals aveo reported earnings  days ago whats next for the stock we take a look at earnings estimates for some clues jun   at  am et on zackscom  things in biotech you should learn today june    things in biotech you should learn today june   jun   at  pm et on seeking alpha stock performance review on biotech industry  athersys aveo pharma heat biologics and ignyta stock performance review on biotech industry  athersys aveo pharma heat biologics and ignyta jul   at  am et on pr newswire  prf asset acquisitions accelerate in healthcare sector boosting potential revenue growth asset acquisitions accelerate in healthcare sector boosting potential revenue growth jul   at  am et on pr newswire  prf todays research reports on stocks to watch aveo pharmaceuticals and clean diesel technologies todays research reports on stocks to watch aveo pharmaceuticals and clean diesel technologies jul   at  am et on accesswire aveo pharmaceuticals regulatory decision from european commission expected soon aveo pharmaceuticals regulatory decision from european commission expected soon jul   at  am et on accesswire todays research reports on trending tickers aveo pharmaceuticals and cara therapeutics todays research reports on trending tickers aveo pharmaceuticals and cara therapeutics jun   at  am et on accesswire aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings jun   at  am et on businesswire  bzx biotech stocks showing signs of resurgence biotech stocks showing signs of resurgence jun   at  am et on pr newswire  prf todays research reports on stocks to watch portola and aveo todays research reports on stocks to watch portola and aveo jun   at  am et on accesswire aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma jun   at  am et on businesswire  bzx aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target jun   at  am et on businesswire  bzx aveo oncology announces phase  tinivo trial of tivozanib and opdivo® nivolumab in rcc advances to phase  aveo oncology announces phase  tinivo trial of tivozanib and opdivo® nivolumab in rcc advances to phase  jun   at  am et on businesswire  bzx aveo oncology and biodesix announce results from two investigatorsponsored phase  studies of hgf targeted antibody ficlatuzumab at the  asco annual meeting aveo oncology and biodesix announce results from two investigatorsponsored phase  studies of hgf targeted antibody ficlatuzumab at the  asco annual meeting jun   at  pm et on businesswire  bzx aveo oncology announces completion of a chmp oral explanation for tivozanib as a treatment of firstline renal cell carcinoma aveo oncology announces completion of a chmp oral explanation for tivozanib as a treatment of firstline renal cell carcinoma may   at  am et on businesswire  bzx research reports initiation on biotech stocks  agenus athersys actinium pharma and aveo pharma research reports initiation on biotech stocks  agenus athersys actinium pharma and aveo pharma may   at  am et on pr newswire  prf aveo announces appointment of matthew dallas as chief financial officer aveo announces appointment of matthew dallas as chief financial officer may   at  am et on businesswire  bzx aveo issues statement regarding the passing of lead director henri a termeer aveo issues statement regarding the passing of lead director henri a termeer may   at  am et on businesswire  bzx aveo oncology announces receipt of uspto notice of allowance related to av aveo oncology announces receipt of uspto notice of allowance related to av may   at  am et on businesswire  bzx todays research reports on biotech stocks to watch aveo pharmaceuticals and pharmathene todays research reports on biotech stocks to watch aveo pharmaceuticals and pharmathene may   at  am et on accesswire aveo reports first quarter  financial results and provides business update aveo reports first quarter  financial results and provides business update may   at  am et on businesswire  bzx aveo announces presentations at the  asco annual meeting apr   at  am et on businesswire  bzx aveo pharmaceuticals inc aveo pharmaceuticals inc operates as a biopharmaceutical company which engages in the advancement of therapeutics for oncology and other areas of unmet medical need its products include tivozanib ficlatuzmab av av and av it focuses on the development of its lead candidate tivozanib in north america as a treatment for renal cell carcinoma and other cancers the company was founded by ronald a depinho lynda chin and kenneth e weg on october   and is headquartered in cambridge ma see full profile analyst ratings sell under hold over buy number of ratings  full ratings rbc capital upgrades aveo pharmaceuticals to sector perform mar   at  am et on benzingacom benzingas top upgrades mar   at  am et on benzingacom update rbc capital markets upgrades aveo pharmaceuticals on progress in multiple areas mar   at  am et on benzingacom competitors name chg  market cap amgen inc  b arqule inc  m regeneron pharmaceuticals inc  b biogen inc  b bristolmyers squibb co  b competitor data provided by partner content trending tickers powered by bzun  momo  gnca  hal  cmg  advanced search stocks columns authors topics no results found video center learn morestoryful a division of news corp which owns marketwatch is a leading social media services company headquartered in dublin ireland storyful combines world class journalism with industryleading technology to discover verify and acquire original content and provide the ontheground sources news and media organizations need to tell the stories that matter to their audience aveonasdaq cm stock quote  aveo pharmaceuticals inc  bloomberg markets error could not add to watchlist x  watchlist aveo pharmaceuticals inc aveous nasdaq cm usd   as of  am edt  open  day range    volume  previous close  wk range     yr return  before its here its on the bloomberg terminal learn more open  day range    volume  previous close  wk range     yr return  ytd return  current pe ratio ttm  earnings per share usd ttm  market cap m usd  shares outstanding m  pricesales ttm  dividend indicated gross yield  sector health care  price change  industry pharmaceuticals biotechnology  life sciences  price change  related videos there are currently no related videos for this ticker please check back later company news press releases  aveo cancer drug tivozanib clears safety review  investopedia there are currently no news stories for this ticker please check back later  asset acquisitions accelerate in healthcare sector boosting potential revenue growth  aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings  biotech stocks showing signs of resurgence  aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma  eusa pharma receive positive opinion from the chmp for tivozanib for the firstline treatment of advanced renal cell carcinoma  aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target  aveo oncology announces phase  tinivo trial of tivozanib and opdivo® nivolumab in rcc advances to phase   aveo oncology and biodesix announce results from two investigatorsponsored phase  studies of hgf targeted antibody  aveo oncology announces completion of a chmp oral explanation for tivozanib as a treatment of firstline renal cell carcinoma  aveo announces appointment of matthew dallas as chief financial officer there are currently no press releases for this ticker please check back later profile aveo pharmaceuticals inc is a biopharmaceutical company focused on discovering developing and commercializing cancer therapeutics the companys lead product candidate is an oral inhibitor of the vascular endothelial growth factor or vegfreceptors address  east kendall streetcambridge ma united states phone  website wwwaveopharmacom executives board members michael p bailey presidentceo matthew d dallas matt chief financial officer michael n needle chief medical officer karuna rubin vplegal affairssecretary show more market report aveo pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing aveo pharmaceuticals inc  product pipeline review   apr    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs aveo pharmaceuticals inc  product pipeline review   provides an overview of the aveo pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of aveo pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of aveo pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of aveo pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the aveo pharmaceuticals incs pipeline productsreasons to buyevaluate aveo pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of aveo pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the aveo pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of aveo pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of aveo pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of aveo pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresaveo pharmaceuticals inc snapshotaveo pharmaceuticals inc overviewkey informationkey factsaveo pharmaceuticals inc  research and development overviewkey therapeutic areasaveo pharmaceuticals inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  partnered productspartnered productscombination treatment modalitiespipeline products  outlicensed productsoutlicensed productscombination treatment modalitiesaveo pharmaceuticals inc  pipeline products glanceaveo pharmaceuticals inc  late stage pipeline productsfiling rejectedwithdrawn productscombination treatment modalitiesphase iii productscombination treatment modalitiesaveo pharmaceuticals inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesaveo pharmaceuticals inc  early stage pipeline productspreclinical productscombination treatment modalitiesdiscovery productscombination treatment modalitiesaveo pharmaceuticals inc  drug profilestivozanibproduct descriptionmechanism of actionrd progressficlatuzumabproduct descriptionmechanism of actionrd progressavproduct descriptionmechanism of actionrd progressavproduct descriptionmechanism of actionrd progressavproduct descriptionmechanism of actionrd progressgpproduct descriptionmechanism of actionrd progressavproduct descriptionmechanism of actionrd progressmonoclonal antibody to antagonize fgfr for cancerproduct descriptionmechanism of actionrd progressmonoclonal antibody to antagonize fgfr for cancerproduct descriptionmechanism of actionrd progressmonoclonal antibody to target notch for cancerproduct descriptionmechanism of actionrd progressmonoclonal antibody to target notch for cancerproduct descriptionmechanism of actionrd progressmonoclonal antibody to target notch for cancerproduct descriptionmechanism of actionrd progressaveo pharmaceuticals inc  pipeline analysisaveo pharmaceuticals inc  pipeline products by targetaveo pharmaceuticals inc  pipeline products by route of administrationaveo pharmaceuticals inc  pipeline products by molecule typeaveo pharmaceuticals inc  pipeline products by mechanism of actionaveo pharmaceuticals inc  recent pipeline updatesaveo pharmaceuticals inc  dormant projectsaveo pharmaceuticals inc  discontinued pipeline productsdiscontinued pipeline product profilesavtivozanibaveo pharmaceuticals inc  company statementaveo pharmaceuticals inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesaveo pharmaceuticals inc key informationaveo pharmaceuticals inc key factsaveo pharmaceuticals inc  pipeline by indication aveo pharmaceuticals inc  pipeline by stage of development aveo pharmaceuticals inc  monotherapy products in pipeline aveo pharmaceuticals inc  partnered products in pipeline aveo pharmaceuticals inc  partnered products combination treatment modalities aveo pharmaceuticals inc  outlicensed products in pipeline aveo pharmaceuticals inc  outlicensed products combination treatment modalities aveo pharmaceuticals inc  filing rejectedwithdrawn aveo pharmaceuticals inc  phase iii aveo pharmaceuticals inc  phase ii aveo pharmaceuticals inc  phase i aveo pharmaceuticals inc  preclinical aveo pharmaceuticals inc  discovery aveo pharmaceuticals inc  pipeline by target aveo pharmaceuticals inc  pipeline by route of administration aveo pharmaceuticals inc  pipeline by molecule type aveo pharmaceuticals inc  pipeline products by mechanism of action aveo pharmaceuticals inc  recent pipeline updates aveo pharmaceuticals inc  dormant developmental projectsaveo pharmaceuticals inc  discontinued pipeline products aveo pharmaceuticals inc subsidiarieslist of figuresaveo pharmaceuticals inc  pipeline by top  indication aveo pharmaceuticals inc  pipeline by stage of development aveo pharmaceuticals inc  monotherapy products in pipeline aveo pharmaceuticals inc  partnered products in pipeline aveo pharmaceuticals inc  pipeline by top  target aveo pharmaceuticals inc  pipeline by top  route of administration aveo pharmaceuticals inc  pipeline by top  molecule type aveo pharmaceuticals inc  pipeline products by top  mechanism of action  companies mentioned in this reportaveo pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc aveo pharmaceuticals inc  product pipeline review   purchase this report aveo pharmaceuticals inc  product pipeline review   published pages publisher report code may   global markets direct asdr published may      pages       publisher  global markets direct     report code  asdr descriptiondesc contentcont figures  tablesfiguresfig related reportsrelated free samplesample aveo pharmaceuticals inc  product pipeline review  summarythe new report aveo pharmaceuticals inc  product pipeline review  ’ provides an overview of the aveo pharmaceuticals inc’s pharmaceutical research and development focusthe report provides comprehensive information on the therapeutics under development by aveo pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsthe new report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from the new report proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datascope the report provides a snapshot of the pipeline therapeutic landscape of aveo pharmaceuticals inc the report provides overview of aveo pharmaceuticals inc including its business description key facts and locations and subsidiaries the report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activities the report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages the report assesses aveo pharmaceuticals inc’s pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule type the report features aveo pharmaceuticals inc’s outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to buy evaluate aveo pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline gain strategically significant competitor information analysis and insights to formulate effective rd strategies identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage identify and understand important and diverse types of therapeutics under development for aveo pharmaceuticals inc identify potential new clients or partners in the target demographic plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics devise corrective measures for pipeline projects by understanding aveo pharmaceuticals inc’s pipeline depth and focus of pipeline therapeutics develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope purchase this report us  euro € gbp £ user pdf us  site pdf us  enterprise pdf us  add to cart   lowest price guarantee license and delivery order process  question about this report this report can be of interest as well nonsmall cell lung cancer nsclc drugs market forecast  published june   report code asdr mark your calendar nd drug development forum  september   september boston united states market report aveo pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing aveo pharmaceuticals inc  product pipeline review   may    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs aveo pharmaceuticals inc  product pipeline review   provides an overview of the aveo pharmaceuticals incs pharmaceutical research and development focusthe report provides comprehensive information on the therapeutics under development by aveo pharmaceuticals inc complete with analysis by stage of development drug target mechanism of action moa route of administration roa and molecule type the report also covers the descriptive pharmacological action of the therapeutics its complete research and development history and the dormant and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites clinical trial registries conferences sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information additionally various dynamic tracking processes ensure that the most recent developments are captured on a real time basisthe report helps in identifying and tracking emerging players in the market and their portfolios enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantagenote certain sections in the report may be removed or altered based on the availability and relevance of datareport scopethe report provides a snapshot of the pipeline therapeutic landscape of aveo pharmaceuticals incthe report provides overview of aveo pharmaceuticals inc including its business description key facts and locations and subsidiariesthe report features descriptive drug profiles for the pipeline products which includes product description descriptive moa rd brief licensing and collaboration details  other developmental activitiesthe report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stagesthe report assesses aveo pharmaceuticals incs pipeline therapeutics based on drug target mechanism of action moa route of administration roa and molecule typethe report features aveo pharmaceuticals incs outlicensed and partnered product portfolio and summarizes its dormant and discontinued projectsreasons to get this reportevaluate aveo pharmaceuticals incs strategic position with total access to detailed information on its product pipelinegain strategically significant competitor information analysis and insights to formulate effective rd strategiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageidentify and understand important and diverse types of therapeutics under development for aveo pharmaceuticals incidentify potential new clients or partners in the target demographicplan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeuticsdevise corrective measures for pipeline projects by understanding aveo pharmaceuticals incs pipeline depth and focus of pipeline therapeuticsdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope table of contentstable of contents list of tables list of figures aveo pharmaceuticals inc snapshot aveo pharmaceuticals inc overview key information key facts aveo pharmaceuticals inc  research and development overview key therapeutic areas aveo pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities pipeline products  outlicensed products outlicensed productscombination treatment modalities aveo pharmaceuticals inc  pipeline products glance aveo pharmaceuticals inc  late stage pipeline products phase iii productscombination treatment modalities aveo pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities aveo pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities discovery productscombination treatment modalities aveo pharmaceuticals inc  drug profiles tivozanib hydrochloride product description mechanism of action rd progress ficlatuzumab product description mechanism of action rd progress av product description mechanism of action rd progress av product description mechanism of action rd progress av product description mechanism of action rd progress gp product description mechanism of action rd progress av product description mechanism of action rd progress monoclonal antibody to antagonize fgfr for cancer product description mechanism of action rd progress monoclonal antibody to antagonize fgfr for cancer product description mechanism of action rd progress monoclonal antibody to target notch for cancer product description mechanism of action rd progress monoclonal antibody to target notch for cancer product description mechanism of action rd progress monoclonal antibody to target notch for cancer product description mechanism of action rd progress aveo pharmaceuticals inc  pipeline analysis aveo pharmaceuticals inc  pipeline products by target aveo pharmaceuticals inc  pipeline products by route of administration aveo pharmaceuticals inc  pipeline products by molecule type aveo pharmaceuticals inc  pipeline products by mechanism of action aveo pharmaceuticals inc  recent pipeline updates aveo pharmaceuticals inc  dormant projects aveo pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles av tivozanib hydrochloride aveo pharmaceuticals inc  company statement aveo pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesaveo pharmaceuticals inc key information aveo pharmaceuticals inc key facts aveo pharmaceuticals inc  pipeline by indication  aveo pharmaceuticals inc  pipeline by stage of development  aveo pharmaceuticals inc  monotherapy products in pipeline  aveo pharmaceuticals inc  partnered products in pipeline  aveo pharmaceuticals inc  partnered products combination treatment modalities  aveo pharmaceuticals inc  outlicensed products in pipeline  aveo pharmaceuticals inc  outlicensed products combination treatment modalities  aveo pharmaceuticals inc  phase iii  aveo pharmaceuticals inc  phase ii  aveo pharmaceuticals inc  phase i  aveo pharmaceuticals inc  preclinical  aveo pharmaceuticals inc  discovery  aveo pharmaceuticals inc  pipeline by target  aveo pharmaceuticals inc  pipeline by route of administration  aveo pharmaceuticals inc  pipeline by molecule type  aveo pharmaceuticals inc  pipeline products by mechanism of action  aveo pharmaceuticals inc  recent pipeline updates  aveo pharmaceuticals inc  dormant developmental projects aveo pharmaceuticals inc  discontinued pipeline products  aveo pharmaceuticals inc subsidiaries list of figuresaveo pharmaceuticals inc  pipeline by top  indication  aveo pharmaceuticals inc  pipeline by stage of development  aveo pharmaceuticals inc  monotherapy products in pipeline  aveo pharmaceuticals inc  partnered products in pipeline  aveo pharmaceuticals inc  pipeline by top  target  aveo pharmaceuticals inc  pipeline by route of administration  aveo pharmaceuticals inc  pipeline by molecule type  aveo pharmaceuticals inc  pipeline products by top  mechanism of action   companies mentioned in this reportaveo pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc aveo home contact us about aveo the human response management team board of directors partnerships our product candidates overview tivozanib ficlatuzumab av av av publications  presentations for media for investors join our team aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more aveo oncology is passionate in our pursuit of improving the lives of patients with cancer find out more now enrolling a phase  study to compare tivozanib hydrochloride to sorafenib in subjects with refractory advanced rcc click here for more information latest events th annual bio ceo  investor conference february   latest news aveo oncology announces m in aggregate gross proceeds from hercules credit facility and atthemarket stock offerings june   aveo oncology announces positive chmp opinion for tivozanib as a treatment of advanced renal cell carcinoma june   aveo oncology announces pivotal phase  tivo study of tivozanib in renal cell carcinoma reaches enrollment target june     aveo pharmaceuticals inc all rights reserved contact us    site map    terms of use    privacy policy yelp yelp sorry you’re not allowed to access this page contact yelp if you keep experiencing issues bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one